What is HC Wainwright’s Estimate for PSTV FY2027 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Equities research analysts at HC Wainwright cut their FY2027 EPS estimates for Plus Therapeutics in a report released on Wednesday, November 26th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.14) per share for the year, down from their prior estimate of ($0.06). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for Plus Therapeutics’ FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.23 EPS.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million.

PSTV has been the topic of a number of other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Wednesday, October 8th. Maxim Group dropped their target price on shares of Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, August 18th. Wall Street Zen raised shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price target on shares of Plus Therapeutics in a research note on Monday. Finally, D Boral Capital upgraded shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.25.

Plus Therapeutics Price Performance

NASDAQ PSTV opened at $0.59 on Monday. The stock has a market capitalization of $81.08 million, a P/E ratio of -0.26 and a beta of 0.77. The business has a 50 day simple moving average of $0.60 and a 200 day simple moving average of $0.48. Plus Therapeutics has a one year low of $0.16 and a one year high of $2.31.

Institutional Trading of Plus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PSTV. Virtu Financial LLC bought a new position in shares of Plus Therapeutics in the first quarter valued at approximately $38,000. Susquehanna International Group LLP bought a new position in Plus Therapeutics during the 3rd quarter valued at $46,000. Jane Street Group LLC bought a new position in Plus Therapeutics during the 2nd quarter valued at $41,000. Scientech Research LLC purchased a new position in Plus Therapeutics during the 3rd quarter worth $100,000. Finally, Altium Capital Management LLC bought a new stake in shares of Plus Therapeutics in the 3rd quarter worth $628,000. 3.28% of the stock is owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.